Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.41 |
| ▸ | GALK1 | P51570 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL110183 | 0.87 | ATR (0.46) | NPC1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL110162 | 0.86 | KMT2A (0.47) | MAPTRAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL110547 | 0.85 | LMNA (0.53) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL15800338 | 0.85 | MAPT (0.41) | NPC1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL15800339 | 0.82 | MAPT (0.41) | NPC1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL139223 | 0.80 | MAPT (0.47) | NPC1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL109071 | 0.80 | CA12 (0.42) | NPC1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL110726 | 0.80 | KMT2A (0.52) | RAB9AMEN1KMT2AALDH1A1JAK2 | |
| SCHEMBL139120 | 0.79 | AKT1 (0.41) | NPC1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL23958640 | 0.79 | LMNA (0.49) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2370407-B1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| CN-102325752-A | Carbazole and carboline kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2012-01-18 | — | — | CN | disclosed |
| EP-2370407-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010080474-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080474-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | JAK2, JAK1, JAK3 | NPC1 2156/4885MAPT 4508/4885RAB9A 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.